Horario Mundial 

Robert A. Kyle - Pioneer, Researcher, Hematology Groundbreaker

The International Myeloma Foundation, which conducts research and provides education, advocacy, and support for myeloma patients, families, researchers, and physicians worldwide, in 2003 established the Robert A. Kyle Lifetime Achievement Award to "honor the physician who most exemplifies a singular dedication to and compassion for myeloma patients and treatment of their disease."

The International Waldenström Macroglobulinemia Foundation also presents a Robert A. Kyle Award for significant advancements in the understanding and treatment of Waldenström macroglobulinemia — established in 2001. And in Arizona, Mayo Clinic physicians compete for the Robert A. Kyle Award for Excellence in Clinical Investigation — for the most outstanding work in any medical research.

Robert A. Kyle, M.D., was a tireless educator and physician-researcher at Mayo Clinic. In his more than 40 years as a consultant in Internal Medicine and Hematology he trained more than 200 hematologists, and as Emeritus Staff, he continues to play an invaluable role in the mentoring and development of new scientists.

Many of the outstanding hematology clinicians and researchers today at Mayo Clinic and major medical centers around the world are protégés of Dr. Kyle's. In fact, much of the knowledge that exists today in medicine about myeloma and monoclonal abnormalities, as well as the reputation Mayo Clinic has gained as one of the best medical centers in the world for myeloma research and treatment, is due to the work Dr. Kyle began nearly a half a century ago and continues today.

A hematology pioneer, Dr. Kyle discovered two significant conditions, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, laying the groundwork to understand myeloma disease progression.

Dr. Kyle's medical career at Mayo Clinic and achievements in medicine speak to his dedication to excellence and devotion to myeloma patients. In 2001, Dr. Kyle was the first recipient of the Waldenstrom Award for understanding and treatment of Waldenström macroglobulinemia. Among his nearly 100 other honors in medicine: honorary doctorate degree of medicine from Polacky University in the Czech Republic, honorary Doctor of Letters, University of North Dakota, Master of the American College of Physicians, recipient of Mayo Clinic's Henry S. Plummer Distinguished Internist Award and Distinguished Mayo Clinician Award and Mayo Clinic Distinguished Alumni Award, and honorary member of the Royal Society of Pathologists in the United Kingdom. Dr. Kyle’s most recent award was the 2007 David A. Karnofsky Memorial Award, at the American Society of Clinical Oncology Annual Meeting.

He has been co-editor of four editions of Neoplastic Diseases of the Blood and three editions of Myeloma, Biology and Management. He has published more than 2.000 papers and abstracts in medical literature about his research, primarily on myeloma. Dr. Kyle is president of the International Society of Amyloidosis. He also serves as President of the International Myeloma Society. He is a member of the Board of Directors and chairman of the Scientific Advisory Board for the International Myeloma Foundation and a member of the Board of Directors and chairman of the Scientific Advisory Committee for the International Waldenstroem Macroglobulinemia Foundation.

Dr. Kyle has devoted his life's work to patients with multiple myeloma and related disorders. In his efforts to help them, he has gained recognition the world over as a pioneer and a respected leader in the advancement of research, clinical treatment and education about this insidious cancer of the plasma cells in the bone marrow.